Michèle Ollier

Michèle Ollier is the founder of Medicxi Ventures (Jersey) Ltd., holding the title of Partner since 2015.
Current jobs include Chief Executive Officer at Kaerus Bioscience France SASU since 2017, Independent Director at Ipsen SA since 2015, Director at LinguaFlex, Inc., Director at Palladio Biosciences, Inc., Director at Mavalon Therapeutics Ltd. since 2016, Director at Kaerus Bioscience Ltd., Director at Aldena Therapeutics, Inc., Director at Vimela Therapeutics Ltd., and Partner at Medicxi Ventures (Jersey) Ltd. (Switzerland).
Former jobs include Chairman at Funxional Therapeutics Ltd., Chairman at Mind-NRG SARL, Director at Aegerion Pharmaceuticals, Inc. from 2007 to 2011, Director at NormOxys, Inc., Director at Diasome Pharmaceuticals, Inc., Director-International Oncology at Rhone-Poulenc Rorer, Inc. in 2000, Director-Life Sciences Investment at Andera Partners SCA in 2006, Director at OncoEthix SA, Group Director-Lipid Lowering Agents at Bristol-Myers Squibb SARL from 1989 to 1992, Director at Cyrenaic Pharmaceuticals, Inc. from 2010 to 2014, Director-Supervisory Board at Profibrix BV, Director at Sonkei Pharmaceuticals, Inc., Independent Director at Minerva Neurosciences, Inc. from 2014 to 2017, Director at EnCare Biotech BV, Director at Stx Pharma Ltd., Director at Gadeta BV, Director at Kymo Therapeutics Ltd., Director at Abtco BV, Director at Yukin Therapeutics SAS, Director at Pearl River Bio GmbH, Director at Pega-One SAS, Director at Nira Biosciences, Inc., Director at Mavalon Therapeutics France SAS, Director at Epsilon-3 Bio Ltd, Director at Human Antibody Factory Ltd., Director at Villaris Therapeutics, Inc., Manager-CNS Product at Sanofi in 1989, Vice President-International Reproductive Health at Serono SA from 2000 to 2002, and Partner at Index Ventures SA from 2009 to 2016.
Education includes a doctorate from Université Paris Nanterre.